Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (101-110 of 155) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinomaS Négrier, A G Bushmakin, J C Cappelleri, et al.
Journal of the National Cancer Institute|October 6, 1993
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survivalD M Nanus, B J Schmitz-Dräger, R J Motzer, et al.
The British Journal of Dermatology|December 13, 2016
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitorsA Zarbo, V R Belum, V Sibaud, et al.
Cancer Research|July 1, 1992
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapyF P Perera, R J Motzer, D Tang, et al.
Cancer|March 1, 1991
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)R J Motzer, N L Geller, C C Tan, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 22, 2001
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer CenterH S Puc, R Heelan, M Mazumdar, et al.
British Journal of Cancer|May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaR J Motzer, B Escudier, R Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acidA D Hoffman, D Engelstein, T Bogenrieder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
Pageof 16

Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinomaS Négrier, A G Bushmakin, J C Cappelleri, et al.
Journal of the National Cancer Institute|October 6, 1993
Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survivalD M Nanus, B J Schmitz-Dräger, R J Motzer, et al.
The British Journal of Dermatology|December 13, 2016
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitorsA Zarbo, V R Belum, V Sibaud, et al.
Cancer Research|July 1, 1992
Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapyF P Perera, R J Motzer, D Tang, et al.
Cancer|March 1, 1991
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)R J Motzer, N L Geller, C C Tan, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 22, 2001
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer CenterH S Puc, R Heelan, M Mazumdar, et al.
British Journal of Cancer|May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaR J Motzer, B Escudier, R Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acidA D Hoffman, D Engelstein, T Bogenrieder, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 7, 2002
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J Thompson, et al.
Pageof 16